HYCAMTIN 4 mg powder for concentrate for solution for infusion clinical trials

REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) versus Investigator’s Choice (IC) Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)

This study is for women with advanced ovarian (or related) cancer that has come back and isn't responding to platinum-based chemotherapy. Researchers are comparing a new treatment called Luveltamab Tazevibulin with standard chemotherapy to see if it works better and is safe.